Dipexium Pharmaceut (DPRX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Dipexium Pharmaceuticals Reports Second Quarter 2016 Financial Results
August 4, 2016 7:00 AM EDTNEW YORK, Aug. 4, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2016.Â
"In the second quarter we completed enrollment in the OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials of Locilex in patients with mild infections of diabetic foot ulcers (Mild DFI) and expect to have top-line data in September. Pending the results of these trials, we anticipate submitting a New... More
